Incidence and associated factors of the most common obstetric complications in pregnant patients with systemic lupus erythematosus
DOI:
https://doi.org/10.61616/rvdc.v6i3.1155Resumo
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of reproductive age, presenting significant challenges during pregnancy. This condition can lead to serious obstetric complications for both mother and fetus. Objectives: To determine the incidence and associated factors of obstetric complications in pregnant patients with systemic lupus erythematosus. Material and Method: A retrospective, observational, analytical, and cross-sectional study was conducted, comprising 106 pregnant patients diagnosed with systemic lupus erythematosus. Results: The mean age of the patients was 32 years (range: 19–39 years). The incidence of obstetric complications was 30%, including preeclampsia (20.8%), HELLP syndrome (3.8%), intrauterine growth restriction (IUGR) (13.2%), and preterm birth (23.6%). Perinatal mortality was 10.4%. High lupus activity in the first trimester was associated with preeclampsia (OR = 2.38, 95% CI: 1.23–4.59, p = 0.011), while increased activity in the third trimester was linked to IUGR (OR = 2.05, 95% CI: 1.04–4.05, p = 0.037). Prednisone use >10 mg/day increased the risk of maternal infections (OR = 2.72, 95% CI: 1.30–5.70, p = 0.008), whereas hydroxychloroquine use was associated with a reduced incidence of preeclampsia (OR = 0.45, 95% CI: 0.21–0.97, p = 0.033). Conclusions: The incidence of obstetric complications in patients with SLE is high, necessitating early and continuous monitoring of disease activity. Optimizing treatment, including hydroxychloroquine use and careful management of prednisone, can significantly improve maternal and perinatal outcomes.
Referências
Pluig L. La prevalencia de diez enfermedades inflamatorias inmunomediadas (imid) en españa. Rev Esp Salud Pública. 2019;93(14):1–14.
Bermúdez-Marranero W, Vizcaino-Luna Y, Bermúdez-Marranero W. Lupus eritematoso sistémico. Acta Médica del Cent. 2017;11(1):82–95.
10. Tarter L, Bermas BL. Expert Perspective on a Clinical Challenge: Lupus and Pregnancy. Arthritis Rheumatol [Internet]. 20240109a ed. 2024;76(3):321–31. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/37975160
Souza RR, Barreto MDS, Teston EF, Salci MA, Vieira VCL, Marcon SS. Pregnancy loss in women with systemic lupus erythematosus: Grounded Theory. Rev Bras Enferm [Internet]. 20240503a ed. 2024;77(1):e20230225. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/38716908
Cancino-Mesa J, Luna-López A, Casí-Torres J. Lupus eritematoso sistémico en actividad y cociente albúmina / globulina invertido , ¿hallazgo propio de la enfermedad? Rev Cuba Reumatol. 2020;22(e163):1–10.
López DS, Haro SS, Barragán IL. Lupus eritematoso sistémico en el embarazo. ACTA MÉDICA Grup ÁNGELES. 2018;16(4):331–8.
Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med [Internet]. 20190709a ed. 2019;171(3):164–71. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31284305
Paydar K, Niakan Kalhori SR, Akbarian M, Sheikhtaheri A. A clinical decision support system for prediction of pregnancy outcome in pregnant women with systemic lupus erythematosus. Int J Med Inf [Internet]. 20161101a ed. 2017;97:239–46. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27919382
Palmsten K, Simard JF, Chambers CD, Arkema E V. Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatol [Internet]. 2017;56(4):561–9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28013193
Pakhathirathien P, Janjindamai W, Dissaneevate S, Thatrimontrichai A, Maneenil G. Neonatal Outcomes in Pregnant Women with Systemic Lupus Erythematosus: A 13-Year Experience in Southern Thailand. J Trop Pediatr [Internet]. 2021;67(3). Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/34345902
Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, et al. Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus. Arthritis Res Ther [Internet]. 20240309a ed. 2024;26(1):63. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/38459603
Kwok, L.W., Tam, L.S., Zhu, T., Li, E.K., Suen, J.J., Chan, Y.Y. (2018). Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus. 27(7): 118-124. doi:10.1177/0961203318777720.
Smyth, A., Oliveira, G.H., Lahr, B.D., Bailey, K.R., Norby, S.M., Garovic, V.D. (2019). A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clinical Journal of the American Society of Nephrology. 14(5): 772-780. doi:10.2215/CJN.12091217.
Moroni, G., Quaglini, S., Banfi, G., Caloni, M., Finazzi, S., Ambroso, G., Ponticelli, C. (2017). Pregnancy in lupus nephritis. American Journal of Kidney Diseases. 39(5): 1065-1072. doi:10.1053/j.ajkd.2016.08.011.
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 Abril Burgueño Ontiveros, Mary Flor Diaz Velázquez , Abril Arellano Llamas

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.


















